A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours

被引：0
|
作者：
Alison M. Schram
Leena Gandhi
Monica M. Mita
Lars Damstrup
Frank Campana
Manuel Hidalgo
Enrique Grande
David M. Hyman
Rebecca S. Heist
机构：
[1] Memorial Sloan Kettering Cancer Center,
[2] New York University Perlmutter Cancer Center,undefined
[3] Cedars-Sinai Medical Center,undefined
[4] Merck Serono,undefined
[5] Sanofi-Aventis,undefined
[6] Beth Israel Deaconess Medical Center,undefined
[7] Hospital Universitario Ramon y Cajal,undefined
[8] Massachusetts General Hospital,undefined
来源：
British Journal of Cancer | 2018年 / 119卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1471 / 1476
页数：5
相关论文
共 50 条
  • [1] A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
    Schram, Alison M.
    Gandhi, Leena
    Mita, Monica M.
    Damstrup, Lars
    Campana, Frank
    Hidalgo, Manuel
    Grande, Enrique
    Hyman, David M.
    Heist, Rebecca S.
    BRITISH JOURNAL OF CANCER, 2018, 119 (12) : 1471 - 1476
  • [2] A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
    Grilley-Olson, J. E.
    Bedard, P. L.
    Fasolo, A.
    Cornfeld, M.
    Cartee, L.
    Razak, A. R. Abdul
    Stayner, L. -A.
    Wu, Y.
    Greenwood, R.
    Singh, R.
    Lee, C. B.
    Bendell, J.
    Burris, H. A.
    Del Conte, G.
    Sessa, C.
    Infante, J. R.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (06) : 740 - 749
  • [3] A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
    J. E. Grilley-Olson
    P. L. Bedard
    A. Fasolo
    M. Cornfeld
    L. Cartee
    A. R. Abdul Razak
    L.-A. Stayner
    Y. Wu
    R. Greenwood
    R. Singh
    C. B. Lee
    J. Bendell
    H. A. Burris
    G. Del Conte
    C. Sessa
    J. R. Infante
    Investigational New Drugs, 2016, 34 : 740 - 749
  • [4] Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.
    Infante, Jeffrey R.
    Gandi, Leena
    Shapiro, Geoffrey
    Rizvi, Naiyer
    Burris, Howard A.
    Bendell, Johanna C.
    Baselga, Jose
    Hsu, Karl
    von Richter, Oliver
    Locatelli, Giuseppe
    Asatiani, Ekaterine
    Heist, Rebecca S.
    CANCER RESEARCH, 2013, 73 (08)
  • [5] Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.
    Heist, Rebecca Suk
    Gandhi, Leena
    Shapiro, Geoffrey
    Rizvi, Naiyer A.
    Burris, Howard A.
    Bendell, Johanna C.
    Baselga, Jose
    Yerganian, Scott B.
    Hsu, Karl
    Ogden, Janet
    Vincent, Loic
    von Richter, Oliver
    Locatelli, Giuseppe
    Asatiani, Ekatherine
    Infante, Jeffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
    Juric, Dejan
    Krop, Ian
    Ramanathan, Ramesh K.
    Wilson, Timothy R.
    Ware, Joseph A.
    Bohorquez, Sandra M. Sanabria
    Savage, Heidi M.
    Sampath, Deepak
    Salphati, Laurent
    Lin, Ray S.
    Jin, Huan
    Parmar, Hema
    Hsu, Jerry Y.
    Von Hoff, Daniel D.
    Baselga, Jose
    CANCER DISCOVERY, 2017, 7 (07) : 704 - 715
  • [7] Phase Ib study of the oral PI3Kδ inhibitor linperlisib in patients with advanced solid tumors
    Li, Jin
    Xue, Junli
    Liu, Tianshu
    Feng, Yi
    Xu, Nong
    Huang, Jianjin
    Yin, Yongmei
    Zhang, Jun
    Mou, Haibo
    Shentu, Jiangzhong
    Bao, Hanying
    Xu, Zusheng
    Xu, Zuhong
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (02) : 241 - 251
  • [8] Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
    Shunsuke Kondo
    Masaomi Tajimi
    Tomohiko Funai
    Koichi Inoue
    Hiroya Asou
    Vinay Kumar Ranka
    Volker Wacheck
    Toshihiko Doi
    Investigational New Drugs, 2020, 38 : 1836 - 1845
  • [9] Phase I Dose-escalation Trial of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B), Combined with an mTOR Inhibitor, Temsirolimus, in Patients with Advanced Solid Tumors
    Naing, A.
    Mita, M.
    Komarnitsky, P.
    Milner, A.
    von Richter, O.
    Ogden, J.
    Piha-Paul, S.
    Fu, S.
    Asatiani, E.
    Kurzrock, R.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 187 - 187
  • [10] Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors (vol 7, pg 704, 2017)
    Baselga, Jose
    CANCER DISCOVERY, 2018, 8 (11) : 1491 - 1491
12345